A- A A+

(...) Today, the FDA issued a Drug Safety Communication alerting health care providers and patients of the increased risk of serious side effects when combining these particular MAT drugs with benzodiazepines – often prescribed to treat anxiety, insomnia, or other conditions – and how to address these risks while continuing to maintain patients on MAT. (FDA – U.S. Food&Drug Administration, 20.09.2017)

https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm576752.htm